
Pembrolizumab Plus cCRT Elicits Durable Antitumor Activity in Unresectable Stage III NSCLC
Pembrolizumab (Keytruda) paired with concurrent chemoradiation (cCRT) continued to showcase antitumor activity with manageable safety in patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC), according to data from the …